OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bardia on Current Approaches to HER2+ Breast Cancer Management

June 19th 2024

Aditya Bardia, MD, MPH, FASCO, discusses standard first-, second-, and third-line HER2-positive metastatic breast cancer management approaches.

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer

June 19th 2024

Giuseppe Curigliano, MD, PhD, discusses findings from the phase 3 DESTINY-Breast06 trial of T-DXd in HER2-low or HER2-ultralow metastatic breast cancer.

Dr Lobbous on Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer Leptomeningeal Metastases

June 19th 2024

Mina Lobbous, MD, MPH, on tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases from HER2-positive breast cancer.

Dr Biran on Current Unmet Needs in Relapsed/Refractory Multiple Myeloma

June 18th 2024

Noa Biran, MD, discusses the investigation of belantamab mafodotin plus bortezomib and dexamethasone in multiple myeloma.

Dr Hantel on Socioeconomic Influences on First-Line Treatment in AML

June 18th 2024

Andrew Hantel, MD, discusses the influence of race/ethnicity and socioeconomic status on the timeliness of first-line treatment in acute myeloid leukemia.

Dr Forsyth on Leptomeningeal Disease in HER2+ Breast Cancer and TNBC

June 18th 2024

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.

Dr Svoboda on the Investigation of huCART19-IL18 in Relapsed/Refractory Lymphoma

June 18th 2024

Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.

Dr Bellmunt on Avelumab Maintenance in Advanced Urothelial Carcinoma With Low Tumor Burden

June 18th 2024

Joaquim Bellmunt, MD, PhD discusses findings from a post-hoc analysis for avelumab maintenance in advanced urothelial carcinoma with low tumor burden.

Dr Mateos on Belantamab Mafodotin Plus Bortezomib/Dexamethasone in R/R Myeloma

June 18th 2024

María-Victoria Mateos, MD, PhD, discusses findings for belantamab mafodotin plus bortezomib and dexamethasone.

Dr Marshall on Updates in CRC Following the 2024 ASCO Annual Meeting

June 17th 2024

John L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.

Dr Grivas on Key Updates in Genitourinary Cancer Management

June 17th 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

Dr Raje on the DREAMM-7 and DREAMM-8 Trials in Multiple Myeloma

June 17th 2024

Noopur S. Raje, MD, and Yan Leyfman, MD, discuss the phase 3 DREAMM-7 and DREAMM-8 trials on OncLive News Network: On Location.

Dr Choudhury on the Evaluation of Treatment Interruption After Response in mHSPC

June 17th 2024

Atish D. Choudhury, MD, PhD, on a phase 2 trial evaluating ADT interruption in metastatic hormone-sensitive prostate cancer after AR inhibitor response.

Dr Levy on the Clinical Application of ADCs in NSCLC Following ASCO 2024 Data

June 17th 2024

Benjamin Levy, MD, and Yan Leyfman, MD, discuss the clinical application of antibody-drug conjugates in non–small cell lung cancer.

Dr Tarantino on Research in HR+ Breast Cancer

June 17th 2024

Paolo Tarantino, MD, and Yan Leyfman, MD, discuss ongoing investigations into the treatment of HR+ breast cancer presented at the 2024 ASCO Annual Meeting.

Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL

June 16th 2024

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.

Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma

June 16th 2024

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.

Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL

June 15th 2024

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis

June 15th 2024

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.

Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma

June 14th 2024

Sundar Jagannath, MBBS, discusses outcomes with linvoseltamab vs teclistamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.